Gibson Dunn Advises Gyre Therapeutics on $300M All-Stock Acquisition of Cullgen

"Gibson Dunn advised Gyre Therapeutics on its acquisition of Cullgen in an all‑stock transaction valued at about $300 million (press release dated March 3, 2026). The deal was led by partners Branden Berns and Ryan Murr with associates Evan Shepherd, Lauren Navarro, Hunter Michielson, and Lauren Romagnoli; Pamela Lawrence Endreny, Rachel Kleinberg and Elizabeth Johnson advised on tax; Bradley Smith on antitrust; David Wolber on international trade; and Sean Feller on benefits."

Gibson Dunn advised Gyre Therapeutics, Inc. in its acquisition of Cullgen Inc. The all‑stock transaction is valued at approximately $300 million; Gyre Therapeutics is a commercial‑stage biopharmaceutical company focused on fibrosis‑first therapies and acquired Cullgen as part of that strategy. Participating Gibson Dunn lawyers (seniority and practice area as stated in the press release): - Branden Berns — partner (corporate) - Ryan Murr — partner (corporate) - Evan Shepherd — associate (corporate) - Lauren Navarro — associate (corporate) - Hunter Michielson — associate (corporate) - Lauren Romagnoli — associate (corporate) - Pamela Lawrence Endreny — partner (tax) - Rachel Kleinberg — partner (tax) - Elizabeth Johnson — associate (tax) - Bradley Smith — partner (antitrust) - David Wolber — partner (international trade) - Sean Feller — partner (benefits)

Menu

Gibson Dunn Advises Gyre Therapeutics on $300M All-Stock Acquisition of Cullgen

Read the full story

Menu

Gibson Dunn Advises Gyre Therapeutics on $300M All-Stock Acquisition of Cullgen

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads